EUVIMEDEUVIMED entdecken
Crossref

Effectiveness of Nirmatrelvir/Ritonavir or Molnupiravir Use in Immunocompromised Patients on B-Cell–Depleting Therapy With COVID-19: A Target Trial Emulation Study

Cassandra Calabrese iD, Yifan Wang iD, Abhijit Duggal, Shuaiqi Huang iD, Yiying Fan iD, Shravan Kethireddy, Gretchen L Sacha iD, Leonard Calabrese, Xiaofeng F Wang iD

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Cassandra Calabrese und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Antiviral Agents, Hydroxylamines, Ritonavir. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunocompromised patients, especially those receiving B–cell–depleting therapy (BCDT), remain at high risk for severe coronavirus disease 2019 (COVID–19). Although monoclonal antibodies showed benefit pre–Omicron, the real–world effectiveness of the oral antivirals in BCDT recipients is unclear.

Methods

We emulated a target trial using the Cleveland Clinic electronic health record. Adult patients (≥18 years) with immune–mediated inflammatory diseases who received rituximab or ocrelizumab and tested positive for severe acute respiratory syndrome coronavirus 2 between 19 December 2021 and 30 June 2025 were eligible. The primary endpoint was hospitalization or death within 21 days; the secondary endpoint was death within 90 days. Propensity scores adjusted for confounding, and Weighted Cox regression models were used to evaluated treatment effects.

Results

Among 255 853 COVID–19 cases, 876 met criteria for the nirmatrelvir/ritonavir cohort (411 treated, 465 untreated) and 566 for the molnupiravir cohort (91 treated, 475 untreated). In the nirmatrelvir/ritonavir cohort, 18 (4.4%) of treated versus 43 (9.2%) of untreated patients were hospitalized or died within 21 days. After weighting, nirmatrelvir/ritonavir reduced the hazard by 44% (hazard ratio [HR], 0.56; 95% confidence interval [CI], 0.31–0.99). In the molnupiravir cohort, 6 (6.6%) of treated and 46 (9.7%) of untreated patients met the primary endpoint; the weighted HR was 0.56 (95% CI, 0.24–1.33), not statistically significant.

Conclusions

Early outpatient nirmatrelvir/ritonavir significantly lowers the risk of COVID–19–related hospitalization or death in patients on BCDT. Molnupiravir showed a nonsignificant trend toward benefit. These findings support prioritizing nirmatrelvir/ritonavir for high–risk immunocompromised populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentAntiviral AgentsHydroxylaminesRitonavirImmunocompromised HostCOVID-19CytidineProlineB-LymphocytesHumansMaleFemaleMiddle AgedAgedAntibodies, Monoclonal, HumanizedSARS-CoV-2AdultRituximabTreatment Outcome

Stichwörter der Autor:innen

B–cell–depleting therapyCOVID-19antiviral medicationimmunocompromisedtarget trial emulation

Substanzen

Antiviral AgentsHydroxylaminesRitonavirmolnupiravirAntibodies, Monoclonal, HumanizedCytidineRituximabProlineocrelizumab

Autor:innen und Institutionen

  • Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Mathematics and Statistics, Cleveland State University, Cleveland, Ohio, USA.
  • Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Cassandra Calabrese, Yifan Wang, Shuaiqi Huang, Yiying Fan, Gretchen L Sacha, Xiaofeng F Wang

Zitieren

APA

Calabrese, C., Wang, Y., Duggal, A., Huang, S., Fan, Y., Kethireddy, S., Sacha, G. L., Calabrese, L., & Wang, X. F. (2026). Effectiveness of Nirmatrelvir/Ritonavir or Molnupiravir Use in Immunocompromised Patients on B-Cell–Depleting Therapy With COVID-19: A Target Trial Emulation Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf521

Vancouver

Calabrese C, Wang Y, Duggal A, Huang S, Fan Y, Kethireddy S, et al. Effectiveness of Nirmatrelvir/Ritonavir or Molnupiravir Use in Immunocompromised Patients on B-Cell–Depleting Therapy With COVID-19: A Target Trial Emulation Study. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf521

BibTeX
@article{Calabrese2026,
  author = {Calabrese, Cassandra and Wang, Yifan and Duggal, Abhijit and Huang, Shuaiqi and Fan, Yiying and Kethireddy, Shravan and Sacha, Gretchen L and Calabrese, Leonard and Wang, Xiaofeng F},
  title = {Effectiveness of Nirmatrelvir/Ritonavir or Molnupiravir Use in Immunocompromised Patients on B-Cell–Depleting Therapy With COVID-19: A Target Trial Emulation Study},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf521}
}
Kostenlos starten →